USD 0.21
(-23.88%)
Year | Net Income | Net Income Growth |
---|---|---|
2023 | -114.33 Million USD | -389.35% |
2022 | -23.36 Million USD | 73.58% |
2021 | -88.42 Million USD | -86.08% |
2020 | -47.51 Million USD | 73.39% |
2019 | -178.59 Million USD | 0.0% |
Year | Net Income | Net Income Growth |
---|---|---|
2024 Q1 | -24.37 Million USD | -13.91% |
2024 Q2 | -37.58 Million USD | -54.17% |
2023 Q1 | -30.75 Million USD | -71.96% |
2023 Q3 | -35.52 Million USD | -33.32% |
2023 Q2 | -26.64 Million USD | 13.35% |
2023 FY | -114.33 Million USD | -389.35% |
2023 Q4 | -21.4 Million USD | 39.77% |
2022 Q2 | -17.83 Million USD | -95.1% |
2022 Q1 | -9.14 Million USD | -907.2% |
2022 FY | -23.36 Million USD | 73.58% |
2022 Q4 | -17.88 Million USD | -183.18% |
2022 Q3 | 21.5 Million USD | 220.53% |
2021 FY | -88.42 Million USD | -86.08% |
2021 Q1 | -22.1 Million USD | -86.08% |
2021 Q4 | 1.13 Million USD | 178.42% |
2021 Q3 | -1.44 Million USD | 93.47% |
2021 Q2 | -22.1 Million USD | 0.0% |
2020 Q3 | -11.87 Million USD | 0.0% |
2020 Q1 | -11.87 Million USD | 73.39% |
2020 FY | -47.51 Million USD | 73.39% |
2020 Q4 | -11.87 Million USD | 0.0% |
2020 Q2 | -11.87 Million USD | 0.0% |
2019 Q2 | -44.64 Million USD | 0.0% |
2019 Q3 | -44.64 Million USD | 0.0% |
2019 FY | -178.59 Million USD | 0.0% |
2019 Q1 | -44.64 Million USD | 0.0% |
2019 Q4 | -44.64 Million USD | 0.0% |
Name | Net Income | Net Income Difference |
---|---|---|
Amgen Inc. | 6.71 Billion USD | 101.702% |
AstraZeneca PLC | 5.95 Billion USD | 101.92% |
Biogen Inc. | 1.16 Billion USD | 109.847% |
Gilead Sciences, Inc. | 5.66 Billion USD | 102.018% |
MIRA Pharmaceuticals, Inc. | -11.98 Million USD | -854.162% |
Scilex Holding Company | -114.33 Million USD | -0.0% |